Targeting Phospholipase D4 Attenuates Kidney Fibrosis

Area of Science:

• Nephrology
• Molecular Biology
• Immunology

Background:

• Phospholipase D4 (PLD4) is significantly upregulated in chronic progressive kidney fibrosis.
• The precise function of PLD4 in kidney fibrosis remains largely unknown.

Purpose of the Study:

• To investigate the role of PLD4 in kidney fibrosis.
• To explore PLD4 as a potential therapeutic target for kidney fibrosis.

Main Methods:

• Genetic silencing of PLD4 in mice (global and conditional).
• Investigated effects on immune responses, TGF-β signaling, and protease expression (neutrophil elastase).
• Utilized siRNA to target PLD4 therapeutically in folic acid-induced kidney fibrosis models.
• Employed immunoprecipitation/mass spectrometry and coimmunoprecipitation to identify PLD4 interacting proteins.

Main Results:

• PLD4 overexpression was confirmed in fibrotic murine and human kidneys.
• Genetic silencing of PLD4 protected mice from kidney fibrosis development.
• PLD4 knockout modulated immune responses and attenuated TGF-β signaling and fibrotic markers.
• Therapeutic PLD4 inhibition reduced kidney fibrosis and associated molecular changes.
• PLD4 was found to bind proteins interacting with TrkA, a receptor involved in MAPK signaling.

Conclusions:

• PLD4 plays a critical role in the development of kidney fibrosis.
• Inhibition of PLD4 represents a promising therapeutic strategy for reversing kidney fibrosis.
• PLD4 targeting may activate protease-mediated extracellular matrix degradation.